Drugs in Dev.
Cardiology/Vascular Diseases
IND Enabling
United Kingdom 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Aerami Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Vectura Signs Agreement with Aerami Therapeutics Inc
Details : Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 08, 2020
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Aerami Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement


